Meibomian Gland Dysfunction (MGD)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Azura Ophthalmics
Azura OphthalmicsIsrael - Tel Aviv
1 program
1
AZR-MD-001 VehiclePhase 21 trial
Active Trials
NCT03972501CompletedEst. Dec 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Azura OphthalmicsAZR-MD-001 Vehicle

Clinical Trials (1)

NCT03972501Azura OphthalmicsAZR-MD-001 Vehicle

An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)

Start: Oct 2019Est. completion: Dec 2020
Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space